Fulvestrant Powder Pharmaceutical Raw Materials Drugs for Breast Cancer

» Pharmaceutique » Les médicaments anti-tumeur » Fulvestrant Powder Pharmaceutical Raw Materials Drugs for Breast Cancer

  • Caractéristiques

Buy Fulvestrant Powder Selective Estrogen Receptor Degrader Drug for Breast Cancer Online

 

Fulvestrant Specification

Nom du produit: Fulvestrant
NO CAS: 129453-61-8
la norme: USP35
Natural/Synthetic: Synthetic
Niveau: Pharmaceutical grade
Content: 99%
Apparence: poudre blanche
Emballage: 10G/Aluminum foil bag
Catégorie: Matières premières pharmaceutiques
Industrie: Médicaments
Champ: Steroid anti-estrogen drugs
Deferred product: Fulvestrant injection
Use: Estrogen receptor-positive locally advanced or metastatic mammary glands that can be used after anti-estrogen adjuvant therapy or during treatment, or after menopause (including natural menopause and artificial menopause) in anti-estrogen therapy cancer.
Utilisation et dosage: 1. Adult females (including elderly women): The recommended dose is once a month, once 250mg. There is a lack of information on the safety and efficacy of Chinese patients at higher doses. 2. Children and Adolescents: Since the safety and effectiveness of this product in children and adolescents have not been determined, the use of this product in this age group is not recommended. 3. Patients with impaired renal function: For patients with mild-to-moderate renal impairment (creatinine clearance ≥ 30 ml/min), there is no need to adjust the dose.

 

What is Fulvestrant?

Fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

Fulvestrant is given by injection into a muscle.

 

Fulvestrant Certificate of Analysis

Nom du produit Fulvestrant
CAS No. 129453-61-8 Emballage externe 10g/foil bag
Date de production 2017-10-22 Durée de conservation 2019-10-18
Norme adoptée USP35
Éléments d’analyse Spécification du Résultats
Apparence A white to off-white crystalline powder Conformes
Identification 1、IR IR should conform to the standard Conformes
Specific rotaion +108°~ +115° 110.8°
6-Keto Fulvestran ≤0.1% 0.05%
∆6,7-Fulvestran ≤0.1% 0.08%
Fulvestrant sulfone ≤0.2% 0.11%
Fulvestrant extended ≤0.3% 0.08%
Fulvestrant sterol dimmer ≤0.8% 0.09%
Fulvestrant β-isomer ≤0.1% 0.06%
Any individual unspecified impurity ≤0.1% 0.03%
Total impurity ≤1.0% 0.7%
FulvestrantA 42%~48% 45.42%
FulvestrantB 52%~58% 54.58%
Résidu sur Lgnition ≤0.1% 0.03%
Drying loss ≤0. 5 % 0.30%
Water ≤0. 5 % 0.26%
Essai 98.0%~102% 99.2%
Conclusion Qualifié

 

Fulvestrant Side Effects

Very common (occurring in more than 10% of people) adverse effects include nausea, injection site reactions, weakness, and elevated transaminases. Common (between 1% et 10%) adverse effects include urinary tract infections, hypersensitivity reactions, loss of appetite, headache, blood clots in veins, hot flushes, vomiting, diarrhea, elevated bilirubin, rashes, and back pain.

Sales Contacts

Tel/Whatsapp: +86 17707567122
Wickr: mollyying
Télégramme: +86 185785209851
Skype: ying_2073
Mail: ying@wumeitech.com

formulaire ( nous reviendrons dès que possible )

prénom:
*
Email:
*
Message:

Vérification:
5 + 3 = ?

Peut-être que vous aimez aussi

  • catégories de produits

  • Messages récents

  • Partager